Research programme: infectious disease vaccines - Immunovaccine

Drug Profile

Research programme: infectious disease vaccines - Immunovaccine

Alternative Names: Bacterial vaccines - Immunovaccine; DepoVax™; DPX-Ebola; Malaria vaccine - Immunovaccine

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoVaccine Technologies
  • Developer Defence Research and Development Canada; Immunovaccine; National Institute of Allergy and Infectious Diseases
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Malaria; Viral haemorrhagic fevers
  • Discontinued Anthrax; Ebola virus infections; Hepatitis B; Influenza virus infections

Most Recent Events

  • 23 Sep 2016 DepoVax malaria vaccine is still in preclinical development for Malaria
  • 16 Sep 2016 Discontinued - Preclinical for Anthrax in Canada (Parenteral)
  • 16 Apr 2015 Discontinued - Preclinical for Ebola virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top